Real-world management and outcomes of 7 million patients with acute coronary syndrome according to clinical research trial enrolment status: a propensity matched analysis
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
AbstractAimsWe aimed to determine whether clinical outcomes and invasive care of acute coronary syndrome (ACS) patients participating in trials differed from those of non-participants, particularly including those who were trial eligible.Methods and resultsWe included all hospitalizations with a principal diagnosis of ACS in the US National Inpatient Sample between January 2004 and September 2015, stratified by trial enrolment and eligibility using the International Classification of Diseases, ninth revision. We conducted propensity score matching to investigate the following outcomes: all-cause mortality; major bleeding; stroke; composite of mortality, stroke, and cardiac complications [major adverse cardiovascular and cerebrovascular events (MACCEs)]; coronary angiography (CA); and percutaneous coronary intervention (PCI). A total of 7 091 179 weighted ACS hospitalizations were analysed, including 19 684 (0.3%) trial participants and 7 071 495 non-participants (3 485 514 of whom were trial eligible). Trial participants were more likely to receive CA [Δ% 28.73%, 95% confidence interval (CI) 27.22–30.24, P < 0.001] and PCI (Δ% 27.13%, 95% CI 24.86–29.41, P < 0.001), with decreased mortality (Δ% −3.51%, 95% CI −4.72 to −2.31, P < 0.001), MACCEs (Δ% −3.04%, 95% CI −4.55 to −1.53, P < 0.001), and bleeding (Δ% −0.89%, 95% CI −1.59 to −0.19, P = 0.013) compared with non-participants. After accounting for eligibility, trial participants were more likely to undergo CA (Δ% 22.78%, 95% CI 21.58–23.99, P < 0.001) and PCI (Δ% 23.95%, 95% CI 21.77–26.13, P < 0.001), and had no difference in mortality (Δ% −0.21%, 95% CI −0.65 to 0.24, P = 0.362).ConclusionAmong ACS patients, trial enrolment was associated with significantly greater invasive care and lower mortality than among matched non-participants. Trial participants were more likely to be invasively managed even when compared with eligible non-participants, even though there was no difference in mortality.
